Assignee
CAYMAN CHEMICAL CO INC
US·18 granted patents·11 pending applications·18 citations·filing 2012–2023
Top patents by PatentIndex Score
29 records- 0186US9487478B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2015·Granted Nov 8, 2016·4 cites·21 claims
- 0285US9180116B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Nov 10, 2015·6 cites·20 claims
- 0382US9440919B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Sep 13, 2016·4 cites·23 claims
- 0480US9701630B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Granted Jul 11, 2017·2 cites·20 claims
- 0577US11884624B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2021·Granted Jan 30, 2024·0 cites·3 claims
- 0675US9890104B2Amine salts of a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2014·Granted Feb 13, 2018·1 cites·10 claims
- 0773US11066361B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2020·Granted Jul 20, 2021·0 cites·3 claims
- 0873US9908834B2Methods of synthesizing a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2017·Granted Mar 6, 2018·1 cites·4 claims
- 0967US10556862B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2018·Granted Feb 11, 2020·0 cites·4 claims
- 1066US11345690B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2019·Granted May 31, 2022·0 cites·3 claims
- 1165US10155716B2Amine salts of a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2017·Granted Dec 18, 2018·0 cites·99 claims
- 1264US2026034111A1NOVEL HETEROCYCLES AS sPLA2-X INHIBITORSCAYMAN CHEMICAL CO INC·Filed 2023·Application pending·0 cites
- 1360US9914725B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2014·Granted Mar 13, 2018·0 cites·4 claims
- 1459US10450257B2Methods of synthesizing a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2018·Granted Oct 22, 2019·0 cites·14 claims
- 1559US2017066751A1Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Application pending·0 cites
- 1659US2020002261A1Methods of synthesizing a prostacyclin analogCAYMAN CHEMICAL CO INC·Filed 2019·Application pending·0 cites
- 1758US9126973B2Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2014·Granted Sep 8, 2015·0 cites·51 claims
- 1856US2015315114A1Methods of Synthesizing a Prostacyclin AnalogCAYMAN CHEMICAL CO INC·Filed 2013·Application pending·0 cites
- 1955US2019144435A1Difluorolactam compositions for ep4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2019·Application pending·0 cites
- 2054US2018170918A1Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2018·Application pending·0 cites
- 2153US2017260173A1Difluorolactam compositions for ep4-mediated osteo related diseases and condtionsCAYMAN CHEMICAL CO INC·Filed 2017·Application pending·0 cites
- 2253US2013079375A1Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseasesCAYMAN CHEMICAL CO INC·Filed 2012·Application pending·0 cites
- 2349US10729810B2Methods, systems, and compositions for promoting bone growthCAYMAN CHEMICAL CO INC·Filed 2014·Granted Aug 4, 2020·0 cites·16 claims
- 2447US9676712B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 13, 2017·0 cites·24 claims
- 2546US2015322107A1Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteinsCAYMAN CHEMICAL CO INC·Filed 2015·Application pending·0 cites
- 2646US2015323542A1Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteinsCAYMAN CHEMICAL CO INC·Filed 2015·Application pending·0 cites
- 2745US9708287B2Chiral compounds, compositions, products and methods employing sameCAYMAN CHEMICAL CO INC·Filed 2015·Granted Jul 18, 2017·0 cites·18 claims
- 2842US9688627B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 27, 2017·0 cites·24 claims
- 2940US2019048086A1Anti-citrullinated hla polypeptide antibodies and uses thereofCAYMAN CHEMICAL CO INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CAYMAN CHEMICAL CO INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →